Patents by Inventor Peter T. Meinke

Peter T. Meinke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210353607
    Abstract: The development of a new, targeted drug delivery paradigm coupled to improved PI3K inhibitors (e.g., PI3K? inhibitors) represents a significant advance in cancer therapy. Provided herein are compounds, such as compounds of Formula (I) and (II), and pharmaceutically acceptable salts, hydrates, solvates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, and prodrugs thereof. The compounds provided herein are PI3K (e.g., PI3K?) inhibitors and are therefore useful for the treatment and/or prevention of various diseases (e.g., proliferative diseases such as cancer). Also provided herein are nanoparticles and nanogels (e.g., P-selectin targeting nanoparticles) comprising PI3K inhibitors, such a compound described herein. In certain embodiments, a nanoparticle or nanogel described herein encapsulates a compound described herein for targeting delivery to cancer cells or tumors.
    Type: Application
    Filed: October 4, 2019
    Publication date: November 18, 2021
    Applicants: Sloan-Kettering Institute for Cancer Research, Tri-lnstitutional Therapeutics Discovery Institute, Inc.
    Inventors: Makoto Fushimi, Maurizio Scaltriti, Daniel Alan Heller, Carles Monterrubio Martinez, Amaia Arruabarrena Aristorena, Peter T. Meinke, Michael Andrew Foley, Yasutomi Asano, Kazuyoshi Aso, Hiroki Takahagi, Yosef Shamay, Jose Manuel Baselga Torres, Yusuke Sasaki, Mayako Michino
  • Patent number: 8338458
    Abstract: Fused aromatic compounds of Formula I are PPAR gamma agonists or partial agonists and are useful for weekly dosing in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: December 25, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Peter T. Meinke, Andrew Denker, Gary E. Meininger, Naoto Uemura, John A. Wagner, Steven Charnick
  • Patent number: 8017605
    Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
    Type: Grant
    Filed: June 10, 2009
    Date of Patent: September 13, 2011
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Soumya P. Sahoo, Meng-Hsin Chen, Kevin D. Dykstra, Hiroo Koyama, Peter T. Meinke, Stephen J. O'Keefe, Ginger Xu-qiang Yang
  • Publication number: 20110105430
    Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: (A) are inhibitors N of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
    Type: Application
    Filed: June 8, 2009
    Publication date: May 5, 2011
    Inventors: Soumya P. Sahoo, Meng-Hsin Chen, Kevin D. Dykstra, Hiroo Koyama, Peter T. Meinke, Stephen J. O'keefe, Ginger Xu-Qiang Yang
  • Patent number: 7834036
    Abstract: Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dyslipidermia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Grant
    Filed: March 3, 2006
    Date of Patent: November 16, 2010
    Assignee: Merck Sharp & Dohme Corp
    Inventors: Harold B. Wood, Peter T. Meinke, Guo Q. Shi, Yong Zhang
  • Patent number: 7807692
    Abstract: Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: October 5, 2010
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: James F. Dropinski, Peter T. Meinke, Guo Q. Shi, Yong Zhang
  • Publication number: 20100168164
    Abstract: Phenoxyphenyl and phenoxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Application
    Filed: June 30, 2006
    Publication date: July 1, 2010
    Inventors: James F. Dropinski, Peter T. Meinke, Guo Q. Shi, Yong Zhang
  • Publication number: 20100130521
    Abstract: Fused aromatic compounds of Formula I are PPAR gamma agonists or partial agonists and are useful for weekly dosing in the treatment or control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Application
    Filed: May 2, 2008
    Publication date: May 27, 2010
    Applicant: MERCK SHARP & DOHME COPORATION
    Inventors: Peter T. Meinke, Andrew Denker, Gary E. Meininger, Naoto Uemura, John A. Wagner, Steven Charnick
  • Publication number: 20090325953
    Abstract: Compounds described by the chemical formula (I) or pharmaceutically acceptable salts thereof: are inhibitors of p38 and are useful in the treatment of inflammation such as in the treatment of asthma, COPD, ARDS, rheumatoid arthritis, rheumatoid spondylitis, osteoarthritis, gouty arthritis and other arthritic conditions; inflamed joints, eczema, psoriasis or other inflammatory skin conditions such as sunburn; inflammatory eye conditions including conjunctivitis; pyresis, pain and other conditions associated with inflammation.
    Type: Application
    Filed: June 10, 2009
    Publication date: December 31, 2009
    Inventors: Soumya P. Sahoo, Meng-Hsin Chen, Kevin D. Dykstra, Hiroo Koyama, Peter T. Meinke, Stephen J. O'Keefe, Ginger Xu-qiang Yang
  • Patent number: 7625933
    Abstract: Indoles of Formula I having —X-aryl-(CH2)x-oxazolidinedione and —X-heteroaryl-(CH2)x-oxazolidinedione substituents on the N atom of the indole ring, where x is 0 or 1, and —X— is a bond or —CH2—, and their thiazolidinedione analogs, are PPAR gamma agonists or partial agonists and are useful in the treatment and control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Grant
    Filed: June 28, 2005
    Date of Patent: December 1, 2009
    Assignee: Merck & Co., Inc.
    Inventors: Kun Liu, Peter T. Meinke, Harold B. Wood
  • Publication number: 20090069385
    Abstract: Pyridinyloxyphenyl and pyridinyloxybenzyl oxazolidine-2,4-diones and thiazolidine-2,4-diones are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Application
    Filed: July 14, 2006
    Publication date: March 12, 2009
    Inventors: Peter T. Meinke, Guo Q. Shi, Harold B. Wood
  • Publication number: 20080262035
    Abstract: The present invention relates to carboxylic acid derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.
    Type: Application
    Filed: July 11, 2005
    Publication date: October 23, 2008
    Inventors: Prasun K. Chakravarty, Steven L. Colletti, Raffaele Ingenito, Peter T. Meinke, Alessia Petrocchi, Christian Steinkuhler
  • Publication number: 20080242597
    Abstract: The present invention relates to novel thiazolyl peptide antibiotics capable of treating serious bacterial infections in mammals, and particularly, in humans. Some of the analogs can also be versatile intermediates for the preparation of new derivatives with useful antibacterial activity.
    Type: Application
    Filed: October 19, 2007
    Publication date: October 2, 2008
    Inventors: Kun Liu, Peter T. Meinke, Fengqi Abe Zhang
  • Publication number: 20080221157
    Abstract: The present invention relates to ketone derivatives that are inhibitors of histone deacetylase (HDAC). The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further, the compounds of the present invention are useful for treating neurodegenerative diseases, schizophrenia and stroke among other diseases.
    Type: Application
    Filed: July 11, 2005
    Publication date: September 11, 2008
    Applicants: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P ANGE, MERCK & CO. INC.
    Inventors: Prasun K. Chakravarty, Steven L. Colletti, Raffaele Ingenito, Philip Jones, Peter T. Meinke, Ester Muraglia, Alessia Petrocchi, Michael Rowley, Rita Scarpelli, Christian Steinkuhler
  • Patent number: 7414067
    Abstract: This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.
    Type: Grant
    Filed: March 24, 2004
    Date of Patent: August 19, 2008
    Assignees: Merck & Co. Inc., Evotec OAI
    Inventors: Edward Andrew Boyd, Michael H. Fisher, Maria L. Garcia, Gregory J. Kaczorowski, Peter T. Meinke, William H. Parsons, Stephen Price, John Stibbard
  • Publication number: 20080194586
    Abstract: Fused aromatic compounds of Formula (I) are PPAR gamma agonists or partial agonists and are useful in the treatment or control of type II diabetes, including hyperglycemia, dylipidermia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Application
    Filed: March 3, 2006
    Publication date: August 14, 2008
    Inventors: Harold B. Wood, Peter T. Meinke, Guo Q. Shi, Yong Zhang
  • Patent number: 7393960
    Abstract: Indoles having aryloxyalkanoic acid substituents or arylalkanoic acid substituents are agonists or partial agonists of PPAR gamma and are useful in the treatment and control of hyperglycemia that is symptomatic of type II diabetes, as well as dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Grant
    Filed: August 28, 2003
    Date of Patent: July 1, 2008
    Assignee: Merck & Co., Inc.
    Inventors: John J. Acton, III, Peter T. Meinke, Harold B. Wood, Regina M. Black
  • Publication number: 20080132500
    Abstract: Certain water-soluble thiazolyl peptides are antibiotic capable of treating serious bacterial infections in mammals, and particularly, in humans. Some of the analogs can also be employed as versatile intermediates for the preparation of new derivatives with useful antibacterial activity.
    Type: Application
    Filed: October 19, 2007
    Publication date: June 5, 2008
    Inventors: Kun Liu, Peter T. Meinke, James F. Dropinski, Libo Xu
  • Publication number: 20080119531
    Abstract: Indoles of Formula I having —X-aryl-(CH2)x-oxazolidinedione and —X-heteroaryl-(CH2)x-oxazolidinedione substituents on the N atom of the indole ring, where x is 0 or 1, and —X— is a bond or —CH2—, and their thiazolidinedione analogs, are PPAR gamma agonists or partial agonists and are useful in the treatment and control of type II diabetes, including hyperglycemia, dyslipidemia, hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, and obesity that are often associated with type 2 diabetes.
    Type: Application
    Filed: June 28, 2005
    Publication date: May 22, 2008
    Inventors: Kun Liu, Peter T. Meinke, Harold B. Wood
  • Patent number: 7348348
    Abstract: Aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are sodium channel blockers; pharmaceutical compositions that include an effective amount of the aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds and a pharmaceutically acceptable carrier, and a method of treatment of acute pain, chronic pain, visceral pain, inflammatory pain, or neuropathic pain, as well as initable bowel syndrome, Cnohns disease, epilepsy, partial and generalized tonic seizures, multiple sclerosis, bipolar depression, and tachy-arrhythmias by the administration of an effective amount of aryl-link-aryl thiazolidine-dione and aryl-link-aryl oxazolidine-dione compounds are described.
    Type: Grant
    Filed: April 25, 2003
    Date of Patent: March 25, 2008
    Assignee: Merck & Co. Inc.
    Inventors: Howard C. H. Kuo, Michelle B. Ayer, Prasun K. Chakravarty, Peter T. Meinke, William H. Parsons, Sriram Tyagarajan